A quarter in change

AddLife's interim report for Q2 2022 is now available online at the company website. The interim report can be downloaded in pdf version. Visit reports-en.add.life/interim-report-q2-2022 (https://reports-en.add.life/interim-report-q2-2022/start/)

• Net sales decreased by 9 percent to SEK 2,079m (2,276), of which acquired growth amounted to 13 percent. The COVID-19 related net sales decreased by 88 percent. The organic growth, excluding net sales related to COVID-19, was 4 percent.
• EBITA decreased by 28 percent to SEK 240m (332), corresponding to an EBITA-margin of 11.6 percent (14.6).
• Profit after tax decreased by 57 percent to SEK 76m (178).
• Earnings per share amounted to SEK 0.63 (1.47).  
• Cash flow from operating activities amounted to SEK 206m (200).
• During the quarter, two acquisitions, BioCat GmBh and O'Flynn Medical Ltd, were completed and after the end of the quarter, one more acquisition, JK Lab Nordic AB, were completed. In total, these acquisitions are estimated to contribute with annual net sales of approximately SEK 180m and approximately 60 employees.

• Net sales increased by 16 percent to SEK 4,658m (4,012), of which acquired growth amounted to 30 percent. The COVID-19 related net sales decreased by 59 percent. The organic growth, excluding net sales related to COVID-19, was 3 percent.
• EBITA increased by 3 percent to SEK 675m (658), corresponding to an EBITA-margin of 14.5 percent (16.4).
• Profit after tax decreased by 26 percent to SEK 301m (404).
• Earnings per share amounted to SEK 2.47 (3.46). Earnings per share for the last 12 months amounted to SEK 5.07 (6.03).
• Cash flow from operating activities amounted to SEK 538m (384).
• The equity ratio was 36 percent (40).
• Return on working capital (P/WC) amounted to 74 percent (95).
• During the interim period, four acquisitions were made and another after the end of the interim period. The acquisitions are expected to contribute with annual net sales of approximately SEK 855m.
• AddLife's new President and CEO Fredrik Dalborg will start on September 1st.

Stockholm, July 15, 2022
AddLife AB (publ)

For more information, contact;
Kristina Willgård, CEO, kristina.willgard@add.life,+46 70 510 12 23
Christina Rubenhag, CFO, christina.rubenhag@add.life,++46 70 546 72 22
www.add.life (https://www.add.life/en/)

Teleconference
Investors, analysts and the media are invited to a teleconference at which CEO Kristina Willgård and CFO Christina Rubenhag will present the interim report. The presentation will be given in English and take about 20 minutes. after which there will be an opportunity to ask questions. The meeting will be recorded and made available online. If this is your first time using Teams, you will be asked to download an app.

The teleconference will be at 10 a.m. CET on July 15, 2022
If you wish to participate via teleconference, please follow this link>> (https://teams.microsoft.com/l/meetup-join/19%3ameeting_NTk3MmE1YWUtNWE1ZS00MmZlLWI0ZDUtMzEzZDExNWNlMjY2%40thread.v2/0?context=%7b%22Tid%22%3a%2220971130-9feb-4ac0-96f1-e7fbd0d840e4%22%2c%22Oid%22%3a%2205bf2cfc-31f1-4624-9e44-f9752b6af674%22%7d)
Or call in (only sound) +46 8 505 376 58 Conference-ID: 915 124 356#

The presentation is also available on AddLife YouTube >> (https://www.youtube.com/channel/UC_YiKbKavYICoTU37Y0C8pg)

AddLife is an independent player in the Life Science industry that offers high-quality products, services and advice to both the private and public sectors, mainly in the Nordic region and rest of Europe. AddLife has about 2,200 employees in some 85 operating subsidiaries. The Group currently has net sales of approximately SEK 9 billion. AddLife shares are listed on Nasdaq Stockholm.

This information is information that AddLife AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication, through the agency of the contact person set out above, at 15 July 2022 at 07:45 a.m. CET.